Drug intelligence / Profile preview

coal tar + triamcinolone acetonide

Development stage: Unknown
Modality: Small Molecules
Administration: Topical

Overview

Coal tar + triamcinolone acetonide is a topical medication that combines the keratoplastic properties of coal tar with the anti-inflammatory effects of triamcinolone acetonide (a corticosteroid). This combination is used to treat various dermatological conditions including psoriasis, eczema, dermatitis, and lichen planus. Coal tar helps slow rapid skin cell turnover and reduce inflammation, while triamcinolone acetonide provides additional anti-inflammatory effects. The combination appears to have synergistic effects, allowing for reduced corticosteroid concentration and minimizing potential side effects.

Targets

GR (Glucocorticoid receptor)AHR (Aryl hydrocarbon receptor)

Beyond the preview

Go deeper on coal tar + triamcinolone acetonide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on coal tar + triamcinolone acetonide.

Explore the full profile